TSG101 and Alzheimer disease: This study supports the hypothesis that disrupted ESCRT function affects the trafficking of APP and its proteolytic derivatives, such as Aβ, and demonstrates that impairing TSG101-dependent processes leads to rapid-onset neurodegeneration in brain areas impacted in AD.